X
COGT icon

Xponance’s Cogent Biosciences COGT Stock Holding History

Xponance’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$634K Buy
16,376
+3,087
+23% +$108K ﹤0.01% 989
2026
Q1 		$511K Buy
13,289
+2,345
+21% +$86.6K ﹤0.01% 1009
2025
Q4 		$389K Buy
10,944
+802
+8% +$22.5K ﹤0.01% 1054
2025
Q3 		$146K Buy
+10,142
New +$120K ﹤0.01% 1399

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Xponance's COGT Position: Q2 2026 in Review

Xponance increased its Cogent Biosciences (COGT) stake by 23% in Q2 2026, buying an estimated $108K and bringing the position to 16,376 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #989.

Xponance first reported a position in COGT in Q3 2025 and has held it in 4 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Xponance held 16,376 shares of Cogent Biosciences worth $634K as of Q2 2026.
  • Xponance bought 3,087 Cogent Biosciences shares in Q2 2026, an estimated $108K.
  • Cogent Biosciences made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #989 holding.
  • Xponance first reported a position in Cogent Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.